PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
PACB$2.24-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
| Common Stock · Additional Paid-inCapital · AccumulatedOtherComprehensive Income (Loss) · Accumulated Deficit · TotalStockholders'Equity | |||||||
|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||
| Balance at December 31, 2022 | 226,505 | $227 | $2,099,782 | $(4,765) | $(1,532,340) | $562,904 | |
| Net loss | — | — | — | — | (306,735) | (306,735) | |
| Other comprehensive income | — | — | — | 4,984 | — | 4,984 | |
| Issuance of common stock following milestone achievement | 8,988 | 9 | 84,752 | — | — | 84,761 | |
| Issuance of common stock in acquisition of Apton | 6,121 | 6 | 76,636 | — | — | 76,642 | |
| Issuance of common stock in connection with Apton liquidity event bonus plan | 169 | — | 2,111 | — | — | 2,111 | |
| Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs | 20,125 | 20 | 189,180 | — | — | 189,200 | |
| Issuance of common stock in conjunction with equity plans | 5,836 | 6 | 15,313 | — | — | 15,319 | |
| Share-based compensation expense | — | — | 72,118 | — | — | 72,118 | |
| Balance at December 31, 2023 | 267,744 | $268 | $2,539,892 | $219 | $(1,839,075) | $701,304 | |
| Net loss | — | — | — | — | (309,851) | (309,851) | |
| Other comprehensive income | — | — | — | 203 | — | 203 | |
| Issuance of common stock in conjunction with equity plans | 6,222 | 6 | 7,697 | — | — | 7,703 | |
| Issuance of common stock in conjunction with convertible notes exchange | 20,452 | 20 | 36,179 | 36,199 | |||
| Share-based compensation expense | — | — | 71,036 | — | — | 71,036 | |
| Balance at December 31, 2024 | 294,418 | $294 | $2,654,804 | $422 | $(2,148,926) | $506,594 | |
| Net loss | — | — | — | — | (546,376) | (546,376) | |
| Other comprehensive income | — | — | — | 35 | — | 35 | |
| Issuance of common stock in conjunction with equity plans | 7,538 | 8 | 3,420 | — | — | 3,428 | |
| Share-based compensation expense | — | — | 41,668 | — | — | 41,668 | |
| Balance at December 31, 2025 | 301,956 | $302 | $2,699,892 | $457 | $(2,695,302) | $5,349 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.